Satisfaction/Quality of Life With Rivaroxaban in SPAF (Stroke Prevention in Atrial Fibrillation) Indication

Inclusion Criteria: * Female and male subjects ≥ 18 years of age with a diagnosis of non-valvular atrial fibrillation * Who are treated with Vitamin K antagonists (VKA) with issues for at least the 4 previous weeks (issues are assessed on medical judgment) * Who start treatment with rivaroxaban to prevent stroke or non-CNS (central nervous system) systemic embolism * With anticoagulation therapy planned for at least 6 months Exclusion Criteria: * Contra indication to the use of Xarelto as described in the Summary of Product Characteristics (SmPC); key contra indications are: * Hypersensitivity to the active substance or to any of the excipients listed in SmPC section 6.1. * Lesion or condition at significant risk of major bleeding * Concomitant treatment with any other anticoagulant agent * Clinically significant active bleeding * Hepatic disease associated with coagulopathy and clinically relevant bleeding risk including cirrhotic patients with Child Pugh B and C * Pregnancy and breast feeding